Journal of AdvancedMedical and Dental Sciences Research

Background – OA has high prevalence, especially in the elderly and high rate of disability related to disease makes it a leading cause of morbidity in the elderly. Symptoms in OA include joint pain, stiffness, decreased range of motion etc. Pharmacological treatment is mostly palliative. Rose hip has shown promising results in reducing pain, stiffness and disability in various studies mostly done in scandinavia. The rose hip (or rose haw) is the pseudo fruit of the rose plant. Aim and objectives- To check laboratory parameters and the safety of rosehip extract in patients with osteoarthritis of knee. Materials and methods- Osteoarthritis of knee joint diagnosed according to clinical and radiological criteria of American College of Rheumatlogy (ACR), controlled uncomplicated co-morbid conditions were included in the study while, inflammatory arthritis, traumatic osteoarthritis, ligament injury, severe OA with deformity, fibromyalgia, depression, substantial abnormalities in haematological, hepatic, renal or metabolic functions, Patients who received glucosamine sulphate, chondroitin sulphate, intra-articular hyaluronate, systemic or intra-articular glucocorticoids in 6 weeks preceding enrolment, history of drug or alcohol abuse, cancer, pregnancy and lactation were excluded in the study. Results- Mean Erythrocyte sedimentation rate (ESR) value got reduced in patients of both the groups (p<0.001). ESR decreased from 22.71 ± 6.44 at 0 week to 20.05 ± 4.60 at 12 weeks in Group 1, while it decreased from 21.92 ± 7.6 at 0 week to 20.42 ± 6.97 at 12 weeks in Group 2. Reduction in mean ESR levels was observed to be comparable in both the groups (p> 0.05). Both the groups were comparable as far as safety is concerned and ADR’s reported didn’t require any discontinuation of therapy. Conclusion- The results of our current study are very encouraging in favour of market preparation of rose hip extract as an adjuvant in treatment of osteoarthritis as it leads to no additional safety concerns. However the findings of current study need to be substantiated by larger randomized, placebo-controlled clinical trials.